Our Gal Sal now calls UK home
What started as a three month long service leave adventure turned into five years, then another five years and now former local nurse Sally Lostroh calls the UK home...
Stay updated with breaking news from Relapsing Remitting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
What started as a three month long service leave adventure turned into five years, then another five years and now former local nurse Sally Lostroh calls the UK home...
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential 17.11.2022 / 12:30 CET/CEST The issuer is solely responsible for th...
A CHARITY which represents people with MS has criticised a decision to deny approval of a new drug for treating the condition. The National Institute for Health and Care Excellence (NICE) - the regulator which approves new treatments and drugs for use by the NHS in England and Wales - has provisionally decided not to recommend ozanimod – a new, oral treatment for people with relapsing MS . The treatment would have been used to help those with relapsing multiple sclerosis. Oral treatments for this form of the condition are limited and the MS Society says ozanimod could have benefitte...